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on prostate at a dose of 100Gy in 5 cases and 110Gy in 94 cases. Some type of hormone therapy was administered in 23 cases
(23.2%).
Results. The review was performed between 2011 and 2012. One patient did not have follow-up (treated in 2007). Overall, speciﬁc
and disease free survival at 5 years were 89% (CI 95% 84–92) 98% (CI 95% 96–100) and 93% (CI 95% 89–97) respectively. Biochemical
relapse at 5 years was 9% (CI 95% 5–15). No local relapses were found and only one patient with nodal relapse and one patient
with distant metastasis were observed. Acute toxicities were urinary in 17 pts (17%) 4 of them GIII (4%); rectal in 4 pts (4%).
Chronic toxicities were urinary in 15 pts (15%), 7 of them GIII (7%), 6 of them required catheter, 2 of them required suprapubic
cystostomy and 5 of them underwent transurethral resection.
Conclusions. Although efﬁcacy results are satisfactory, patients are adding up toxicities on both radiotherapy techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.024
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Purpose. Vaginal cuff brachytherapy (VBT) is one of the most widely and settle brachytherapy procedures wordwile. Some groups
advocate a previous rectum cleansing, despite this fact no studies exist analysing the consequences of rectal distention during
VBT. The aim of our study was to deﬁne how the type of rectal content affects its dosimetric values.
Material and methods. CT sets (337) derived from 92 patients treated with HDR-VBT were re-segmented and re-planed for study
purpose under the same parameters. Rectum content on each CT was recorded. Rectum DVH values were extracted and the dose
percentage related to the empty status was calculated. Parametric and non-parametric analysis was carried out according to the
rectal content.
Results. Dose percentages according to the rectal content and related to the empty status were: D0.1cc: feces 101.86, air 113.36,
air + feces 108, contrast 109.49, contrast + air 111.9; D1cc: feces 100.58, air 113.61, air + feces 107.62, contrast 111.75, contrast + air
112.96; D2cc: feces 100.4 air 114.53, air + feces 108.15, contrast 112.99, contrast + air 114.5; D5cc: feces 101.57, air 119.82, air + feces
111.95, contrast 117.6; contrast + air 120.27. Kruskal–Wallis (D5cc, D10cc) andANOVA (Dmax,D0.1cc, D2cc) tests showed signiﬁcant
differences among empty rectums, rectums with feces, and rectums with gas pockets (all p< .00001).
Conclusions. The presence of gas pockets increases rectal doses during vaginal cuff brachytherapy. Maneuvers addressed to reduce
it, like rectal tubes or rectum cleansing, could diminish rectal doses and toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.025
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Introduction. Endobronchial brachytherapy is an option in the treatment of airway tract tumors in centres where had experienced
staff. The indications are: localized endobronchial carcinomas, combined with external irradiation in ﬁrst line treatment of lung
cancers and palliative intention.
Objectives. To report our 5 years experience in brachytherapy for patients with respiratory tract cancer.
Methods. We carried out a retrospective review of our patients who underwent endobronchial brachytherapy from December
2007 to December 2012. Indications were radical, adjuvant and palliative intention. Under sedation, with local anesthesia and by
nasal access, the procedure involves the insertion of an afterloading 5F catheter into bronchus affected in close proximity to an
endoluminal lesion and to perform limited irradiation sparing as much as possible healthy tissues. CT dosimetry was performed
to verify catheter position anddose planning. In patientswith early stages (31.2%),we observed a patientwith complete remission
in a 3-years follow-up period.
Results. A total of 16 patients (14 men and 2 women) were reviewed: 11 with lung cancer, 4 esophagus and one tongue base. Types
of histology identiﬁed were: 12 squamous, 3 adenocarcinoma and only one with different histology. The mean patient’s age was
63.9 (46–79). The stages were: 6.2% 0, 25% I, 25% II, 31.25% III, 12.5% IV. Dose per fraction 500 cGy. One patient did not complete
treatment due to progression with occlusion of the bronchial lumen. One suffered from signiﬁcant toxicity: pneumothorax.
Other patients had minor toxicities: mucositis, dysphagia and cough. All patients who completed treatment showed good clinical
response (100%) and successful local control.
Conclusion. Endoluminal HDR brachytherapy in patients with respiratory tract cancer is a safe and effective treatment for improv-
ing local control and symptoms relief and also with radical intention in early stages.
http://dx.doi.org/10.1016/j.rpor.2013.03.026
